Document is current
Any future updates will be listed below
-
Authors
Calvet, Ferriol https://orcid.org/0000-0003-1841-9881
Blanco Martinez-Illescas, Raquel
Muiños, Ferran https://orcid.org/0000-0002-4651-4168
Tretiakova, Maria https://orcid.org/0000-0002-0819-9638
Latorre-Esteves, Elena S.
Fredrickson, Jeanne
Andrianova, Maria
Pellegrini, Stefano
Huber, Axel Rosendahl
Ramis-Zaldivar, Joan Enric
An, Shuyi Charlotte
Thieme, Elana https://orcid.org/0000-0002-6012-1117
Kohrn, Brendan F. https://orcid.org/0000-0001-9948-2131
Grau, Miguel L.
Gonzalez-Perez, Abel https://orcid.org/0000-0002-8582-4660
Lopez-Bigas, Nuria https://orcid.org/0000-0003-4925-8988
Risques, Rosa Ana https://orcid.org/0000-0002-0291-1858
- License Information
-
More Information
Article History
Received: 29 November 2024
Accepted: 12 August 2025
First Online: 8 October 2025
Competing interests
: R.A.R. is an equity holder at TwinStrand Biosciences Inc. and NanoString Technologies Inc. R.A.R. is named inventor on patent no. 11,479,807 (Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing) owned by the University of Washington and licensed to TwinStrand Biosciences Inc. R.A.R. was a consultant at TwinStrand Biosciences Inc. and received research funding from a joint research grant with TwinStrand Biosciences Inc. and Ovartec GmbH. B.F.K. is an equity holder at NanoString Technologies Inc. The other authors declare no competing interests.
